FP00-0043-00

Fig.1

30 40 A A C U C C U G U C U U G C A U U G C A C U A A G U C U U G C A C U U G U C A C A A A C A G U G C A C C U A C U U C A A ACGTGATT CAGAACGTGAACAGTGTTTGTC 77-91 160 140 150 GUUCUA CA A A GA A A A CA CA GCUA CA A CUGGA GCA UUUA CUGCUG GA UUUA CA GA UGA UUU 200 210 220 - 230 190 UGA A UGGA A UUA A UA A U<u>UA CA A GA A UC C CA A A CUCA C CA G GA UG CUCA CA UUUA A GUUUU</u> ATGTT CTT AGGGTTT GAGTGGTC CTACGAGTGTA AATTCAAAA 198-212 213-227 228-242 260 280 290 A C A UG C C C A A G A A G G C C A C A G A A C UG A A A C A UC UUC A G UG UC UA G A A G A A G A A C U C A A A C TGTACGGGTTCTTCCGG TCTTCTTGAGTTTG 243-257 287-301 320 330 340 360 CUCUGGA GGA A GUGCUA A A UUUA GCUCA A A GCA A A A CUUUCA CUUA A GA CCCA GGGA CU GAGACCTCCTTCACGA GTGAATTCTGGGTCCCTGA 342-356 302-316 390 . 400 UA A UC A G C A A UA UC A A C GUA A UA GUUC UG G A A CUA A A G G G A UC UG A A A C A A C A UUC A UG U | A T T A G T C G T T A 357-371 440 450 460 GUGA A UA UGCUGA UGA GA CA GCA A CCA UUGUA GA A UUUCUGA A CA GA UGGA UUA CCUUUU 520 GUCAAAGCAUCAUCUCAACACUAACUUGAUAAUUAAGUGCUUCCCACUUAAAACAUAUCA 580 590 GGCCUUCUA UUUA UUUA A AUA UUUA AA UUUUA UA UUUA UUGUUGA A UGUA UGGUUUGCUA 630 C C D A UUG D A A C D A UUA UUC UUA A UC UUA A A A C D A D A A A UA UG G A UC UUUUA UG A UUC UUU · 680 690 710 670 740 750 790 800 AUAAAUAUAAAAAAAAAAAA

FP00-0043-00

570

AGUUUUUGAUAGCUUUAUUUUUUAAGUAUUUUAUAUAUUUAUAACUCAUCAUAAAAUAAAG

580

610 UAUAUAUAGAAUCUAAAA

Fig.3




Fig.4




Fig.5




Fig.6





Fig.7








Fig.9




Fig.10




Fig.11




Fig.12





Fig.13


IL-2 342-356



RATIO OF AREAS 79.7%: 22.8%

Fig.14

IL-2 357-371



RATIO OF AREAS 72.7%: 27.3%

Fig.15

IL-4 119-133




Fig.16

IL-4 134-148





Fig.17






Fig.18

IL-4 280-294





Fig. 19



1 Time after adding 10 nM PMA, 0.5 mg/ml anti-human CD3 antibody and anti-human CD28 antibody to cultured Jurkat E6-1 cells

² The concentration of IL-2 in the culture supernatants measured by ELISA using anti-human IL-2 antibody

^{3, 4} Determination of cellular IL-2 expression level by dot blotting using RNA probe complementary to human IL-2 mRNA

Fig.20




Fig.21

IL-2 EXPRESSION





Fig. 22

Fig.23

IL-2 EXPRESSION






Fig.25




Fig.26




Fig.27




Fig.28




Fig.29




Fig.30





Fig.31








Fig.33




Fig.34





Fig.35








Fig.37




Fig.38




Fig.39




Fig.40




Fig.41




Fig.42




Fig.43




Fig.44




Fig.45




Fig.46




Fig.47



Fig.48




Fig.49




Fig.50




Fig.51




Fig.52





Fig.53








Fig.60




Fig.61




Fig.62




Fig.63




Fig.64




Fig.65




Fig.66




Fig.67




Fig.68




Fig.69




Fig.70




Fig.71




Fig.72




Fig.73




Fig.74





Fig.75








Fig.77




Fig.78




Fig.79




Fig.80




Fig.81




Fig.82




Fig.83




Fig.84




Fig.85





Fig.86



The state of the s	
IL-4 mRNA (+); 0/10	IL-2 mRNA (+); 11/11
IL-5 mRNA (+); 0/11	γ -IF mRNA (+); 14/14
IL-10 mRNA (+); 0/9	IL-2 mRNA (+); 11/11 γ -IF mRNA (+); 14/14 TNF- β mRNA (+); 11/11

Fig.88

IL-2 mRNA (+); 6/28

IL-4 mRNA (+); 3/42

Fig.89

γ -IF mRNA (+); 0/11 TNF- β mRNA (+); 0/9	IL-5 mRNA (+); 11/11 IL-10 mRNA (+); 11/11
	IL-5 mRNA (+); 11/11
IL-2 mRNA (+); 0/11	IL-4 mRNA (+); 12/12

Fig.90

IL-2 mRNA (+); 2/28	IL-2 mRNA (+); 3/35
IL-4 mRNA (+); 8/41	IL-4 mRNA (+); 9/42

Fig.91

γ -IF mRNA (+); 9/9 TNF- β mRNA (+); 9/9	IL-10 mRNA (+); 0/9
	IL-5 mRNA (+); 0/8
IL-2 mRNA (+); 10/10	IL-4 mRNA (+); 0/9

Fig.92

IL-2 mRNA (+); 9/24	IL-2 mRNA (+); 11/29
IL-4 mRNA (+); 1/41	IL-4 mRNA (+); 1/48

Fig.93

γ -IF mRNA (+); 0/8 TNF- β mRNA (+); 0/8	IL-10 mRNA (+); 9/9
γ -IF mRNA (+); 0/8	IL-5 mRNA (+); 10/10
IL-2 mRNA (+); 0/7	IL-4 mRNA (+); 9/9

Fig.94

